Evotec

• Just - Evotec Biologics
• Safety assessment Pathology Bioanalysis ADME Abuse liability assessment SEND Integrated pre-clinical development
• API capabilities Material sciences Analytical development and Quality Control Pre-clinical formulation DP Development & Manufacturing Integrated inhalation Integrated CMC
• Analytical development and Quality Control
• DP Development & Manufacturing
• Global Regulatory Affairs Support
• Anti-infectives Immunology and inflammation Metabolic diseases and complications Neurosciences Oncology Rare diseases Respiratory Therapeutic areas
• Metabolic diseases and complications
• Pipeline of product opportunities
• IR & ESG Events
• Data protection for shareholders Annual General Meeting Archive Annual General Meeting
• Data protection for shareholders
• Annual General Meeting Archive
• ESG Performance & Reporting
• Contact IR & ESG

The data-driven R&D Autobahn to Cures

Evotec's new scientific content hub

What you can contribute

How you can participate

Evotec`s 3D cell model platform

Evotec Capital Markets Day - Paradigm Shift in Biologics

2 November 2022 in Redmond / Seattle

PanHunter: Evotec's next-generation multi-omics data analysis platform

Just - Evotec Biologics' J.POD® wins CPhI Pharma Award 2022

Evotec announces agreement with Janssen to develop immune-based therapies

Hamburg, Germany, 26 Jan 2023

Evotec SE announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc

Evotec-partner Sernova provides update on development of iPSC-derived cell therapy for diabetes

London, ON, Canada, 10 Jan 2023